The estrogen receptor alpha (ERa) has been proven to be one of the most important therapeutic targets in breast cancer over the last 30 years. Previous studies pointed out that a natural flavonoid, silibinin, induced apoptosis in human breast cancer MCF-7 cells. In the present study we report that exposure of MCF-7 cells to silibinin led to cell death through the down-regulation of ERa expression. Silibinininduced apoptosis of MCF-7 cells through up-regulation of caspase 6 due to ERa signalling repression was further boosted by ERa antagonist. Moreover, up-regulation of autophagy induced by silibinin accounted for apoptotic exacerbation, being further enhanced by ERa inhibition. Upon ERa activation, series of downstream signalling pathways can be activated. We found that silibinin reduced the expressions of Akt/mTOR and extracellular-signal-related kinase (ERK), which respectively accounted for the induction of autophagy and apoptosis. These effects were further augmented by co-treatment with ERa inhibitor. We conclude that the treatment with silibinin of ERa-positive MCF-7 cells down-regulates the expression of ERa, and subsequently mTOR and ERK signaling pathways, ERa downstream, finally resulting in induction of autophagy and apoptosis.
Introduction
In the modern world, breast cancer is one of the most common malignances in women. It has been known more than a century (1) that breast cancer is associated with cell-surface estrogen receptor (ER). Human ER exists as two subtypes, ERa and ERb, which regulate the transcription of various target genes upon binding to estrogen response elements (ERE) present within the regulatory region of the genes. In most ERa-positive breast cancers, especially in early stages, the expression level of ERa is considerably higher than that in normal breast epithelium (2) . Therefore, targeting the ERa signalling pathway has already become a focal point in the development of breast cancer therapy.
Silibinin (Fig. 1A) , a natural polyphenolic flavonoid, is a major bioactive component of silymarin isolated from the plant milk thistle Silybum marianum (L.) Gaertn. Silibinin has been extensively used for its hepatoprotective effectiveness in Asia and Europe (3, 4) . According to the reports, flavonoids have been shown to be cytotoxic to cancer cells (5, 6) . It has been reported that the estrogen receptor is required for flavonoid-induced cytotoxicity in breast cancer cell lines (7, 8) . Silibinin induces a loss of cell viability in MCF-7 cells. However, underlying mechanism has not been completely elucidated. It is not known if the estradiol-like effect of silibinin contributes to its anti-cancer potency. Therefore, we focused on ERa regulation in the cytotoxicity of silibinin in MCF-7 cells that inherently express high levels of ERa.
Materials and methods

Reagents
Silibinin with a purity of 99% was purchased from Jurong Best Medicine Material (Zhenjiang, Jiangsu, China). The reagent was dissolved in dimethylsulfoxide (DMSO) to make a stock solution. 24 h, and the cell viability was measured by MTT assay, n ¼ 3, mean ± S.E.M, *p < 0.05, compared with silibinin -treated group. (E) The different suppression of silibinin in ERa-high expressive MCF-7 and ERa-low expressing MDA-MB231 (MB231) human breast cancer cells. Compare between the two strains of human breast cancers at the specific concentration of silibinin, **p < 0.01. ERa levels were examined by western blot analysis. (F) Cells were cultured for 24 h and then incubated with different concentrations of MPP (a specific ERa antagonist MPP dihydrochloride) for 1 h, and then silibinin 200 mM was added and cultured for 24 h. The viability was determined by the MTT assay, n ¼ 3, mean ± S.E.M, **p < 0.01, compared with silibinin-treated group. (G) The cells were transfected with control or ERa-targeting siRNA for 48 h, and then incubated with different concentrations of silibinin for 24 h. The viability was measured by MTT assay, n ¼ 3, mean ± S.E.M, *p < 0.05, **p < 0.01, si-ERa compared with si-con group.
MEM and DMEM complete media were used for dilution and the final concentration of DMSO was kept below 0.1% in cell culture, which had no detectable effects on cells. Methylthiazolyldiphenyltetrazolium bromide (MTT), propidiumiodide (PI), RNase A, monodansyl cadaverine (MDC), rhodamine 123, estrogen receptor (ER) antagonist Fulvestrant (ICI 182,780), estrogen receptor alpha (ERa)-specific antagonist MPP 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole-dihydro-chloride, and primary antibody against LC3 were purchased from Sigma Chemical (St. Louis, MO, USA). Polyclonal antibody against ERa was purchased from Proteintech Group (Chicago, IL, USA). Primary antibodies against p62, caspase-6, caspase-8, Bid, Akt1/2, p-Akt1/2, Bcl-2, Bax, cytochrome c, ERK1, p-ERK 1/2, GRB2, Raf, SOS, inhibitor of caspase-activated DNase (ICAD), poly-ADP-ribose polymerase (PARP) and b-actin, as well as horseradish peroxidase-conjugated secondary antibodies, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The SuperSignal West Pico Chemiluminescent Substrate ® used in conjunction with the horseradish peroxidase (HRP) enzyme was purchased from Thermo Scientific (Rockford, IL, USA).
Cells culture
Human breast cancer MCF-7, MDA-MB231 cells and human hepatoma G2 (HepG2) were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). MCF-7 cells were cultured in Minimum Essential Medium (MEM, Gibco, Grand Island, NY, USA), while MDA-MB231 and HepG2 cells were in Dulbecco's Modified Eagle medium (DMEM, Gibco, Grand Island, NY, USA). All media were supplemented with 10% fetal bovine serum (FBS) (Beijing Yuanheng Shengma Research Institution of Biotechnology, Beijing, China), penicillin (100 U/ml) and streptomycin (100 mg/ ml). Cells were incubated at 37 C with 5% CO 2 in a humidified atmosphere. All experiments were performed on logarithmically growing cells.
Fluorescent microscopy of MDC staining
Autofluorescent compound MDC stains acidic lysosomes and thus it is widely used in studies of autophagy together with the measurement of other parameters (9) . The cells were seeded into 24-well cell culture plates (Corning, NY, USA) at a density of 2 Â 10 4 cells per well for 24 h. The cells in culture for another 24 h by the treatments with different reagents were examined. The cells treated were rinsed twice with ice-cold PBS, stained with 0.05 mM MDC solution in the dark at 37 C for 30 min. They were observed with a fluorescence microscope (Olympus, Tokyo, Japan). 
Determination of mitochondrial membrane potential
The mitochondrial membrane potential was examined using the mitochondrial dye rhodamine 123. After incubation with indicated treatments, MCF-7 cells were collected and stained with 1 mg/mL rhodamine 123 at 37 C for 30 min. The fluorescence intensity of the cells was analysed by FACScan flow cytometry.
Transfection of siRNA
MCF-7 cells were transfected with negative control siRNA (NCsiRNA) or siRNA targeting ERa (ERa-siRNA) at a final concentration of 10 nM using siRNA-Mate (GenePharma, Shanghai, China) according to the manufacturer's instructions. The sequences of the ERa-siRNA duplex were as follows: sense strand, 5 0 -GAGGGA-GAAUGUUGAAACATT-3 0 ; antisense strand, 5 0 -UGUUUCAACAUU-CUCCCUCTT-3 0 . The sequences of NC-siRNA duplex were: sense strand, 5 0 -UUCUCCGAACGUGUCACGUTT-3 0 ; antisense strand, 5 0 -ACGUGACACGUUCGGAGAATT-3 0 . The transfected cells were maintained for another 48 h before subsequent experiments.
Western blot analysis
After the indicated treatments, both adherent and floating cells were collected at the predetermined time points and lysed with RIPA lysis buffer (Beyotime, Haimen, Jiangsu, China) supplemented with PMSF (1 mM) for 30 min. After centrifugation at 12,000 Â g for 10 min, the supernatant was collected and the protein concentration was determined with the Bio-Rad protein assay reagent (BioRad, Hercules, CA, USA). The lysates that were adjusted with the total amount of proteins equal were separated on 10e13% SDS-PAGE. The separated protein bands were transferred onto Millipore Immobilon ® -P Transfer Membrane (Millipore Corporation, Billerica, MA, USA). After blocking with 5% skimmed milk at room temperature for 2 h, the membranes were incubated with primary antibodies at 4 C overnight and then with corresponding HRP conjugated secondary antibodies at room temperature for 2 h. After that, the blots were visualized using the SuperSignal West Pico Chemiluminescent Substrate ® purchased from Thermo Scientific (Rockford, IL, USA).
Statistical analysis
All the data and results obtained by at least three independent experiments were expressed as mean ± S.D. Comparisons between groups were determined using Student's t-test. One-tailed p-values are significant when p < 0.05. 
Results
ERa down-regulation was involved in silibinin-induced cytotoxicity of MCF-7 cells
To test the cytotoxicity of silibinin on MCF-7 cells, the cells were cultured with 100e300 mM silibinin for 12, 24, 36 and 48 h. Silibinin was found to decrease the proportion of viable cells in a time and dose-dependent manner with an IC 50 (at 24 h) of 200 mM (Fig. 1B) .
As a flavonoid, silibinin might affect the estrogen receptor signalling pathways (5) . Therefore, we investigated the levels of ERa. Western blot analysis showed that treatment with various concentrations of silibinin for 24 h reduced ERa expression in a concentration-dependent manner (Fig. 1C) . Fulvestrant (ICI 182,780), an estrogen receptor antagonist which blocks both ERa and ERb signalling, was applied with silibinin to examine the effect of estrogen receptor signalling pathway on MCF-7 cell growth. The results showed that ICI 182,780 augmented silibinin-induced MCF-7 cell growth inhibition (Fig. 1D) . To further elucidate the role of ERa, we examined the cytotoxicity of silibinin on two different strains of human breast cancer cells: one is MCF-7 cells with an inherently high expression of ERa and the other is MDA-MB-231 cell with a rather low expression of ERa. MDA-MB-231cells are often utilized as a negative control for the examination of ERa involvement (10) . Western blot analysis of the ERa levels of MCF-7 and MDA-MB-231 indicated, in accordance with the previous reports, that the ERa expression in MCF-7 cells was high, but low in MDA-MB-231 cells (Fig. 1E (a) ).
MTT assay showed that the growth inhibitory effect of silibinin on MCF-7 cells was higher than that on the MDA-MB-231 cells (Fig. 1E (b) ), evidencing the positive correlation between ERa down-regulation and cytotoxicity. The specific ERa-antagonist, MPP (11), dose-dependently augmented silibinin-induced MCF-7 cell growth inhibition (Fig. 1F ), even to a larger extent than ICI 182,780 (Fig. 1D) . Since high dose of MPP (20 mM) alone also inhibited cell proliferation, we chose a lower dose (10 mM) of MPP in the following experiments. To further confirm the cytotoxicity of silibinin in combination with repression of ERa on MCF-7 cells, we transfected the siRNA targeting ERa (si-ERa) into cells ( Fig. 1G (a) ). We found that silencing of ERa markedly enhanced the cytotoxic effect of silibinin (Fig. 1G (b) ). Therefore, silibinin exerted anticancer effects on MCF-7 cells through the inhibition of ERa pathways.
Treatment with MPP enhances silibinin-induced apoptosis of MCF-7 cells
To determine the features of MCF-7 cell growth inhibition, the morphologic changes were examined. Obvious changes of cell nuclei and cell number were observed in the cells treated with 200 mM silibinin plus 10 mM MPP for 24 h when compared with the cells treated with silibinin alone, (Fig. 2A) . PI staining was applied to analysis of the changes of DNA contents: silibinin increased the ratio of cells at subG1 phase in cell cycle at 24 h, while co-treatment with MPP increased the ratio furthermore (Fig. 2B) . These results suggested that apoptosis might be involved in this growth inhibition. It was well documented that many anticancer drugs induced apoptosis following mitochondrial dysfunctions (12) . Therefore, we examined intactness of mitochondrial membranes by rhodamine 123 staining. Decrease in rodamine-123 fluorescence intensity reflects the reduction in mitochondrial transmembrane potential (Djm). Compared with silibinin-treated group, co-treatment with MPP resulted in a further reduction in Djm (Fig. 2C) , indicating that inhibition of ERa markedly enhances the cytotoxicity of silibinin on MCF-7 cells through mitochondrial dysfunction.
Treatment with MPP enhances the cytotoxicity of silibinin through both extrinsic and intrinsic-apoptosis pathways
Western blot assay was carried out to further determine the features of silibinin and MPP-induced MCF-7 cell death. The treatment with silibinin resulted in that extrinsic apoptosis-related protein pro-caspase-8 was cleaved into active caspase-8, as well as Bid was cleaved. MPP further augmented this effect (Fig. 3A) . As for the intrinsic apoptosis pathway, translocation of the anti-apoptotic protein Bcl-2 to mitochondria was markedly decreased in the silibinin-treated group, while the pro-apoptotic translocation of Bax to mitochondria and the release of cytochrome c to cytoplasm were increased. MPP also augmentedthese processes furthermore (Fig. 3B) . The results indicate that the intrinsic apoptosis pathway was also upregulated.
Caspase 3 is the downstream executor of apoptosis in many cells. However, MCF-7 cells were reported to be negative in the expression of caspase-3 (13, 14) . Accordingly, the expressions of pro-caspase 3 and activated caspase 3 were not detected in silibinin-treated MCF-7 cells (Fig. 3C) . It was reported that silibinin activated caspase 3 in HepG2 cells (15) . Therefore, silibinin-treated HepG2 cells were used as a positive control for the detection of caspase 3 (Fig. 3C) . We examined the expression of another common downstream executor of apoptosis, caspase-6, and found that silibinin induced the activation of caspase 6. MPP treatment augmented the cleavage of pro-caspase-6 to caspase-6 furthermore. The substrates of caspase-6, ICAD and PARP, were cleaved accordingly (Fig. 3D ). In conclusion, MPP pre-treatment enhanced both intrinsic and extrinsic apoptotic pathways in silibinin-treated MCF-7 cells.
Inhibition of ERa augmented silibinin-induced MCF-7 cell autophagy
Autophagy is a fundamental cellular pathway by which cytoplasmic materials, including soluble macromolecules and organelles, are delivered into lysosomes for degradation (15) . Autophagy plays an important role in the cellular responses towards stresses such as starvation, hypoxia and DNA damage. The morphologic changes were observed in the MDC-stained cells by fluorescence microscopy. Combined treatment with silibinin and MPP caused an obvious increase in the number of MDC-labelled autophagolysosomes compared with the silibinin alone group (Fig. 4A) . The quantitative analysis of autophagy by MDC flow cytometric analysis showed the consistent results ( Fig. 4B and C) . Microtubuleassociated protein light chain 3 (LC3) is now widely used to monitor autophagy. The levels of LC3 conversion (from cytosolic LC3-I to membrane-bound lipidated LC3-II) or the amounts of LC3-II were examined by immunoblotting analysis (16) . An alternative method for detecting the autophagic flux is the measurement of p62 degradation, since p62 can bind LC3, thus serving as a selective substrate of autophagy (16) . Dose-dependent up-regulation of the conversion from LC3-I to LC3-II and down-regulation of p62 caused by silibinin treatment were observed (Fig. 4D) . Combined use of silibinin with MPP enhanced expressions of LC3-II and conversion from LC3-I to LC3-II significantly increased, while p62 amount was further reduced (Fig. 4E) .
Autophagy promoted apoptosis in MCF-7 cells by the cotreatment with silibinin and MPP
To investigate the crosstalk of apoptosis and autophagy in silibinin and MPP-treated MCF-7 cells, 3 MA, a specific autophagic inhibitor, and rapamycin, an autophagic inducer, were employed. As shown in Fig. 5A , silibinin and MPP-induced cell growth inhibition was further augmented by rapamycin treatment but partially reversed by 3 MA. Western blot analysis showed that the activation of caspase-6 and the cleavage of caspase substrates, PARP and ICAD, caused by cotreatment with MPP and silibinin were reversed by 3 MA treatment (Fig. 5B) . These findings indicated that the autophagy induced by silibinin and MPP co-treatment intensified the apoptotic process in MCF-7 cells.
Combination of silibinin and MPP treatments repressed the downstream signals of ERa
The pathways through Shc-Grb2-Sos (Src homology-growth factor receptor binding protein 2-son of sevenless) for activation of MAPK and are involved in the downsteam of activated ERa (17) . One of them is RAS/ERK pathway, which can induce oncogenic gene expression programs, being often activated in cancer cells. Another is PI3K/Akt pathway which is related with the mammalian target of rapamycin (mTOR). Hou X. and co-workers reported that ERa raised the phosphorylation levels of PI3K, Akt and mTOR in endometrial carcinoma cells (18) . We examined the activation of these two ER downstream signaling pathways.
Western blot analysis showed that PI3K/Akt/mTOR pathway was down-regulated by either silibinin alone or silibinin and MPP co-treatment (Fig. 6A) . As has been demonstrated in many studies, inhibition of mTOR promotes autophagy (19, 20) . Therefore, silibinin enhanced autophagy by down-regulating ERa downstream PI3K/Akt/mTOR pathway.
As shown in Fig. 6B , treatment with MPP obviously reduced the p-ERK expression compared with silibinin alone group. To examine the role of ERK, we pre-treated the cells with ERK inhibitor PD98059, and found that the cytotoxicity was obviously enhanced by ERK inhibition (Fig. 6C and D) . Since p62 degradation and from LC3-I to LC3-II increased, we further confirmed significantly increased autophagy after PD98059 exposure (Fig. 6E) . These findings indicated that apoptotic action of silibinin on MCF-7 cells was mediated through ERa downstream RAS/ERK pathway. EGFR signaling also leads to inhibition of ERK1/2. Crosstalk between EGFR and ER signaling has been established and proved to have significant impact on complex biological processes such as cell growth and cell survival of breast cancer cells. To test the relationship between down-regulation of ERa and EGFR, we examined the changes of expressed EGFR protein levels in MCF-7 cells treated with silibinin with/without MPP. We found that inhibition of ERa with silibinin or/and MPP, the expression levels of EGFR was downregulated as shown in (Fig. 6F) . Thus, the effect of silibinin on ERK is mediated by ERa that may have cross-talk with EGFR.
Discussion
Breast cancer is one of the most frequently diagnosed cancers and the leading cause of death by cancer among females worldwide. To develop breast cancer therapies, targeting of ERa, which is highly expressed in approximately 70% of all breast tumors (21) , is taken as a targeting molecule.
ERa is a member of the steroid receptor superfamily that regulates processes such as growth and differentiation in various target cells by affecting transcription. ERa not only plays an important role in many human tissues and organs, such as mammary gland, genital tract, and central nervous system (22) , but also it has a close correlation with gaining the peak bone mass and maintaining the bone mass (23) . Women who are menopausal or postmenopausal usually produce less ERa, leading to bone loss (24) . However, in the majority of breast cancers, ERa is greatly upregulated than normal breast cells and its expression is a hallmark of hormone-dependent tumor growth (25) . In addition, the presence of elevated levels of ERa in benign breast epithelium appears to indicate an increased risk of breast cancer, suggesting a role for ERa in breast cancer initiation, as well as progression (26) .
Silibinin, which has been used as a liver protectant, induced apoptosis in human breast cancer MCF-7 cells (27) . In this study, we report the evidence for the mechanism of silibinin-induced apoptosis in that downregulation of ERa expression in the MCF-7 cells exposed to silibinin underlies. Consistent with previous reports, silimarin, which contains silibinin as a major component, has been used in the clinical treatment of hepatic diseases and pharmacologic studies have indicated that silymarin is not toxic even at high doses. Besides, pretreatment with silibinin 500 mM significantly inhibited UV-induced apoptosis in HaCaT cells after 9 h incubation (28) . Therefore we believe that silibinin appears to be toxic for cancer cells, but relatively safe for normal ones. ERa receptors are known to exist in cytosol and also as membrane bound-ER. However, in MCF-7 cells transfected with GFP-ERa, the fluorescence of GFP-ERa was observed only in the nucleus (29) . Therefore, it seemed that ERa receptors are mainly found in nucleus.
The mechanism we propose here is supported by the finding that ERa-specific antagonist, MPP, combined with silibinin enhanced all the effects of silibinin on MCF-7 cells. The enhancement with MPP can be interpreted as inhibition of the activity of ERa remaining after downregulation with silibinin. Apoptosis is characterized by the sequential activation of caspase cascades. Caspase 8 is believed to be one of the initiator caspases that can activate downstream caspase-3 (30) . However, MCF-7 cells do not express caspase-3 (13, 14) . Instead, upregulation of the caspase-6 expression was obtained for the MCF-7 cells treated with silibinin in accordance with the report by Kagawa S et al., showing that Baxinduced levels of caspase-6 activation could be used as an evaluation index of apoptosis when the cells did not express caspase-3 (31) .
A number of studies showed relationship between ERa expression and levels of apoptosis related proteins including Bcl-2 and Bax (32e34). The relationships between ERa and apoptosis pathways in silibinin-treated cells observed in the present study indicate that death rate of MCF-7 cells induced by silibinin through the down-regulation of ERa involves both the extrinsic and intrinsic apoptosis pathways.
Estradiol-bound ERa interacts with various signalling molecules such as PI3K (35) and MAP kinases (36) . The PI3K/Akt and MEK/ERK signalling pathways are important downstream pathways of ERa. The observations in the present study that silibinin reduced the phosphorylation levels of both ERK and Akt and that additional treatment with a specific inhibitor of ERK enhanced the cytotoxic effects on MCF-7 cells treated with silibinin and MPP are rationally interpreted, since they are downstream signaling pathways of ERa. Our results are in accordance with the results of Melyssa and coworkers, who reported that MCF-7 breast carcinoma cells promoted survival through activation of PI3K/Akt crosstalk pathway (37) . We therefore conclude that silibinin shows cytotoxic effect against MCF-7 cells through the down-regulation of ERa signalling pathway.
Physiological levels of autophagy are essential for normal cellular homeostasis. The absence of autophagy increases cell death during metabolic stress and on treatment with cytotoxic chemotherapeutic agents. By contrast, excessive levels of autophagy promotes cell death (38) . It is postulated that autophagic cell death induced by some anticancer agents underlines their potential as a new cancer therapy modality (39) . MPP in combination with silibinin activates autophagy which enhances apoptosis in MCF-7 cells. The results are consistent with the notions in several studies in that autophagy is triggered in some cancers in response to various anticancer agents, including As 2 O 3 , tamoxifen and temozolomide (40) .
In conclusion, the present study demonstrates that downregulation of ERa expression by the treatment with silibinin of MCF-7 cells plays a key role in leading the cells to follow ERa-MEK/ ERK and ERa-Akt/mTOR pathways to apoptosis. ERa inhibition with ERa-specific antagonist, MPP, augments autophagy and apoptosis by extrinsic-apoptosis and mitochondrial-apoptosis pathways. Autophagy plays a pro-apoptotic role with the detailed mechanism remaining to be cleared.
In the present study, we highlight just ERa signalling for the silibinin effect. However, it is not known whether the antitumor activity of ERb is involved. Estrogen receptors ERa and ERb share considerable sequence homology yet exert opposite effects on breast cancer cell proliferation. Bin et al. illustrated that modulation of ERb-specific antitumor activity can be considered as a molecular strategy for cancer therapy (41) . It is suggested that the mechanisms of silibinin's toxic effect on MCF-7 cells may also be associated with ERb. Up-regulation of ERb is another mechanism of toxic effect on cancer cells. Studies also have shown that ERb exerts antiproliferative effects in ERa expressing MCF7 cells, probably by initiating degradation of ERa. Meanwhile, ERb-selective agonist DPN inhibited cell growth and induced apoptosis. In addition, there are reports which show that the proliferating MCF-7 cells express both ERa and ERb. In order to examine whether the cytotoxic effect of silibinin is related with ERa, we performed MTT experiments using MDA-MB231 cells that have low expression of ERa and positive ERb as a negative control. MTT assay showed that the growth inhibitory effect of silibinin on MCF-7 cells was higher than that on the MDA-MB-231 cells (Fig. 1E (b) ), evidencing the positive correlation between ERa down-regulation and cytotoxicity. We assume that silibinin also dose-dependently induced cytotoxicity in MDA-MB231 cells and ERb expression in MDA-MB231 cells was increased. In order to prove this hypothesis, further experiments are necessary. Thus, ERb could be another key mechanism of silibinin-induced apoptosis and autophagy in many cell lines as well as MCF-7 cell. Therefore, we are going to use ERb as a target object for future research.
